Figure 2.

Omics approaches for the development of personalized treatments in MM. Cells and biological molecules are obtained from blood, urine and BM samples from heterogeneous populations of MM patients. HMCLs that reflect MM heterogeneity derived from patientsprovide a tool to study drug responses in vitro and are a source of biological molecules for subsequent studies. Analyses of patient and HMCLs samples by omics approaches lead to the identification of biomarkers that allowrisk stratification and predict response to drugs